C3N-00175
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 72.47091034
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.340
- KRAS_SIGNALING_DN+0.320
- ANGIOGENESIS+0.230
- APICAL_SURFACE+0.180
- HEDGEHOG_SIGNALING+0.170
- PANCREAS_BETA_CELLS+0.150
- HYPOXIA+0.140
- KRAS_SIGNALING_UP+0.120
- WNT_BETA_CATENIN_SIGNALING+0.120
- NOTCH_SIGNALING+0.050
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.680
- MYC_TARGETS_V1-0.640
- E2F_TARGETS-0.580
- MYC_TARGETS_V2-0.550
- G2M_CHECKPOINT-0.520
- DNA_REPAIR-0.490
- MTORC1_SIGNALING-0.480
- INTERFERON_ALPHA_RESPONSE-0.450
- PROTEIN_SECRETION-0.450
- MITOTIC_SPINDLE-0.440
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-44-A4SU-01A-11R-A24X-07 | — | cohortA1 | 0.930 |
| 2 | SRR6013488 | — | cohortA1 | 0.929 |
| 3 | TCGA-MN-A4N4-01A-12R-A24X-07 | — | cohortA1 | 0.922 |
| 4 | SRR8613808 | — | D | 0.918 |
| 5 | BS_3T6X4BPC | DNET | — | 0.918 |
| 6 | BS_MQCKXD60 | Glial-neuronal tumor NOS | — | 0.917 |
| 7 | MNG771 | — | — | 0.917 |
| 8 | SRR1516041 | — | — | 0.915 |
| 9 | BS_PQ7CQFYR | Ganglioglioma | — | 0.914 |
| 10 | SRR1375271 | GTEX | — | 0.913 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.340 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.320 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.230 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.170 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| HYPOXIA | 0.140 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.120 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.050 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.040 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.020 | Inavolisib | — uncovered |
| COAGULATION | 0.010 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.010 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.010 | Idelalisib | — uncovered |